Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE)

Study identification

• EU PAS number:
  EUPAS1000000788
• Study ID:
  1000000788
• Official title and acronym:
  Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Belgium

  Brazil

  Bulgaria

  Canada

  Colombia

  Denmark

  Estonia

  Greece

  Ireland

  Italy

  Japan

  Korea, Republic of

  Kuwait

  Mexico

  Norway

  Poland

  Portugal

  Saudi Arabia

  Singapore

  Spain

  Taiwan

  United Arab Emirates

  United Kingdom

  United States
• Study description:
  Study aims to characterise late failures—relapses occurring up to three years after remission is achieved at 12 months of biologic therapy.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Networks

International Severe Asthma Registry

Study timelines

Date when funding contract was signed

Planned:17/11/2023

Actual:17/11/2023

Study start date

Planned:01/03/2023

Actual:17/03/2023

Data analysis start date

Planned:01/07/2025

Actual:30/07/2025

Date of final study report

Planned:15/12/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pharmaceutical companies: AstraZeneca
Other: Optimum Patient Care Global

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable